Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theratechnologies and PDC sign license agreement for women’s health programs
In June 2006, Theratechnologies had granted an option to licence PDC31 which had shown efficacy in vitro and in animal models in pre-term labor. With this exclusive licence
In June 2006, Theratechnologies had granted an option to licence PDC31 which had shown efficacy in vitro and in animal models in pre-term labor. With this exclusive licence
The study enrolled 918 patients (876 of which completed the study) in six emergency departments. The study achieved a sensitivity of 96% and a specificity of 85% with
The Presillion comes in diameters ranging from 2.5-4mm and in lengths ranging from 8-32mm. The Presillion stent system can be used to treat various lesion types: de novo,
Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine. Michael Wells, CEO of Aton Pharma, said: “Cuprimine and Syprine are medically
The improvement of 36% was driven by strong sales of paediatric vaccines, in particular by Quinvaxem, higher sales of travel vaccines and higher license fees and other income.
The second Phase II clinical trial will be a randomized, single-blind, controlled study in 48 healthy adolescents and children. The study will test the rabies monoclonal antibody combination
The California action alleges that Neuralstem and its two founders infringed the company’s US patent for methods of proliferating human neural stem cells and its recently issued US
The new facility will provide StemCyte with increased storage capacity for its supply of plasma-depleted umbilical cord blood (UCB) stem cell products. In addition, the Covina facility will
Since March 1, 2005, Mr Langlois has served as a general partner with PJL CONSEILS, a consulting firm specializing in strategy, corporate development, and M&A activities for healthcare
The company, to be called Daiichi Sankyo Ilac Tikaret, will be headquartered in Istanbul and will initially focus on marketing the osteoporosis medication Evista (Raloxifen). The affiliate in